Initiation of new glucose-lowering therapies may act to reduce physical activity levels: Pooled analysis from three randomized trials
Yates, T. Sargeant, J. A. King, J. A. Henson, J. Edwardson, C. L. Redman, E. Gulsin, G. S. Brady, E. M. Ahmad, E. Stensel, D. J.
Yates, T.
Sargeant, J. A.
King, J. A.
Henson, J.
Edwardson, C. L.
Redman, E.
Gulsin, G. S.
Brady, E. M.
Ahmad, E.
Stensel, D. J.
Abstract
Objective: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown.
Research design and methods: We pooled data (n = 148) from three randomized trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison with sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies, on accelerometer-assessed physical activity.
Results: Liraglutide (mean -1,144 steps/day; 95% CI -2,069 to -220), empagliflozin (-1,132 steps/day; -1,739, -524), and sitagliptin (-852 steps/day; -1,625, -78) resulted in reduced total daily physical activity after 6 months (P < 0.01 vs. control). Moderate- to vigorous-intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity.
Conclusions: The initiation of all glucose-lowering therapies was associated with reduced physical activity, warranting further investigation.
Affiliations
Citations
Altmetric:
Date
2022-08-19
Type
Article
Subject
Collections
Citation
Yates, T., Sargeant, J. A., King, J. A., Henson, J., Edwardson, C. L., Redman, E., Gulsin, G. S., Brady, E. M., Ahmad, E., Stensel, D. J., Webb, D. R., McCann, G. P., Khunti, K., & Davies, M. J. (2022). Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials. Diabetes care, 45(11), 2749–2752. https://doi.org/10.2337/dc22-0888